Open AccessClinical relevance and functional implications for human leucocyte antigen‐g expression in non‐small‐cell lung cancer
Author(s) -
Lin A.,
Zhu C.C.,
Chen H.X.,
Chen B.F.,
Zhang X.,
Zhang J.G.,
Wang Q.,
Zhou W.J.,
Hu W.,
Yang H.H.,
Xu H.H.,
Yan W.H.
Publication year - 2010
Publication title -
journal of cellular and molecular medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.44
H-Index - 130
eISSN - 1582-4934
pISSN - 1582-1838
DOI - 10.1111/j.1582-4934.2009.00858.x
Subject(s) - cytolysis , lung cancer , human leukocyte antigen , hla g , clinical significance , antigen , immunohistochemistry , medicine , immunology , immune system , immunotherapy , cell , lung , biology , pathology , in vitro , cytotoxic t cell , biochemistry , genetics
HLA‐G has been documented both in establishment of anti‐tumour immune responses and in tumour evasion. To investigate the clinical relevance of HLA‐G in non‐small‐cell lung cancer (NSCLC), expression status and potential significance of HLA‐G in NSCLC were analysed. In this study, HLA‐G expression in 101 NSCLC primary lesions and plasma soluble HLA‐G (sHLA‐G) from 91 patients were analysed with immunohistochemistry and ELISA, respectively. Correlations between HLA‐G status and various clinical parameters including survival time were evaluated. Meanwhile, functional analysis of transfected cell surface HLA‐G expression and plasma sHLA‐G form NSCLC patients on natural killer (NK) cell cytolysis were performed. Data revealed that HLA‐G was expressed in 41.6% (42/101) NSCLC primary lesions, while undetectable in adjacent normal lung tissues. HLA‐G expression in NSCLC lesions was strongly correlated to disease stages ( P = 0.002). Plasma sHLA‐G from NSCLC patients was markedly higher than that in normal controls ( P = 0.004), which was significantly associated with the disease stages (I versus IV, P = 0.025; II versus IV, P = 0.029). Patient plasma sHLA‐G level (≥median, 32.0 U/ml) had a significantly shorter survival time ( P = 0.044); however, no similar significance was observed for the lesion HLA‐G expression. In vitro data showed that both cell surface HLA‐G and patient plasma sHLA‐G could dramatically decrease the NK cell cytolysis. Our findings indicated that both lesion HLA‐G expression and plasma sHLA‐G in NSCLC is related to the disease stage and can exert immunosuppression to the NK cell cytolysis, indicating that HLA‐G could be a potential therapeutic target. Moreover, plasma sHLA‐G in NSCLC patients could be used as a prognosis factor for NSCLC.